Ruhi Ali

Ruhi Ali

Auto-generated profile, based on publicly available information

Ruhi Ali

Department of Pharmaceutical Chemistry, DIPSAR, Delhi Pharmaceutical Science and Research University (DPSRU)

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2024 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SASubiya Ambreen
Subiya Ambreen
MUMohammad Umar
Mohammad Umar
ANAaisha Noor
Aaisha Noor
HJHimangini Jain
Himangini Jain
RARuhi Ali
Ruhi Ali

19 April 2016 in Medicinal Chemistry Research
Verified
Journal Article
Closed access
PDF file
NSNadeem Siddiqui
Nadeem Siddiqui
MAMD SHAMSHER ALAM
MD SHAMSHER ALAM
RARuhi Ali
Ruhi Ali
MYMohammad Yar
Mohammad Yar
OAOzair Alam
Ozair Alam

10 April 2024 in Ageing Research Reviews
Verified
Journal Article
Closed access
MUMohammad Umar
Mohammad Umar
YRYasir Rehman
Yasir Rehman
SASubiya Ambreen
Subiya Ambreen
SMSayed Md Mumtaz
Sayed Md Mumtaz
MSMohd Shaququzzaman
Mohd Shaququzzaman
RARuhi Ali
Ruhi Ali

4 August 2021 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
MHMohamad Haider
Mohamad Haider
ACAnjali Chauhan
Anjali Chauhan
STSana Tariq
Sana Tariq
DPDharam Pal Pathak
Dharam Pal Pathak
NSNadeem Siddiqui
Nadeem Siddiqui
RARuhi Ali
Ruhi Ali
Neurodegenerative diseases are complex disorders that cause neuron loss, brain aging and ultimately lead to death. These diseases are difficult to treat because of the complex nature of the nervous system and the available medicines are not able to heal them effectively. This fact implies the needs for novel therapeutics to be designed that are ready to stop or a minimum of retard the neurodegeneration process. These days, computer assisted drug design (CADD) approaches are a passage to extend the drug development efficiency and to reduce time and cost because traditional drug discovery is both time-consuming as well as costly. Computational or in silico methods came up with powerful tools in drug design against neurodegenerative diseases. This review presents the approaches and theoretical basis of CADD. Also, the successful applications of various in silico studies, including homology modeling, molecular docking, quantitative structure activity relationship (QSAR), molecular dynamic (MD), De Novo drug design, Pharmacophore-based drug design, Virtual Screening (VS), LIGPLOT Analysis, In silico ADMET and drug safety prediction, for treating neurodegenerative diseases have also been included in this review. Major emphasis is given to the Alzheimer’s disease and the Parkinson’s disease because these two are the most familiar neurodegenerative diseases.

2 May 2023 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
DPDarakhshan Parveen
Darakhshan Parveen
ADANWESHA DAS
ANWESHA DAS
SAShaista Amin
Shaista Amin
MAM. Mumtaz Alam
M. Mumtaz Alam
MAMymoona Akhter
Mymoona Akhter
MSM. Shaquiquzzaman
M. Shaquiquzzaman
Coronavirus disease (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus and dexamethasone is a glucocorticoid widely used for its treatment. Dexamethasone is not used in non-severe cases due to its immunosuppressant action. So, considering this, Estrogen and Estetrol were tested for the treatment of COVID-19 as they all possess a common steroid ring and dislike dexamethasone, they are immunoenhancer. Virtual screening of test ligands was performed through molecular docking, MM-GBSA, simulations, in silico ADMET and drug-likeness prediction to identify their potential to inhibit the effects of SARS-CoV-2. Results showed that test ligands possess drug-like properties and they are safe as drug candidates. The protein-ligand interaction study revealed that they bind with the amino acid residues at the active site of the target proteins and the test ligands possess better binding potential than Dexamethasone. With protein Mpro, Estetrol and Estrogen showed docking score of −7.240 and −5.491 kcal/mol, and with protein ACE2, Estetrol and Estrogen showed docking score of −5.269 and −4.732 kcal/mol, respectively. Further, MD Simulation was carried out and most of the interactions of molecular docking are preserved during simulation. The prominent interactions that our test ligands showed during MD Simulation are similar to drugs that possess in vitro anticovid activity as shown in recent studies. Hence, our test ligands possessed potential for anticovid activity and they should be further tested through in vitro and in vivo studies for their activity against COVID-19. Communicated by Ramaswamy H. Sarma

15 April 2021 in Current Bioactive Compounds
Verified
Journal Article
Closed access
PDF file
RBRubina Bhutani
Rubina Bhutani
GKGarima Kapoor
Garima Kapoor
DPDharam Pal Pathak
Dharam Pal Pathak
AHAsif Husain
Asif Husain
RKRavi Kant
Ravi Kant
RARuhi Ali
Ruhi Ali
Among the various fused heterocyclic rings, benzothiazole and its analogs have been explored broadly in search of newer therapeutic medicinal agents. The benzothiazole scaffold has been associated with huge biological potential like anticancer, antidiabetic, anti-inflammatory, antitubercular, antiviral, anti-convulsant etc. The occurrence of benzothiazole core in various compounds proves its value in the sphere of pharmaceutical chemistry. The connected research and developments in benzothiazole based chemistry become an active topic for medicinal scientists. A large number of benzothiazole and its heterocyclic derivatives are available in the market and used for the treatment as clinical drugs have been extensively used in practice to treat diverse types of ailments with high therapeutic potential. This review presents the latest therapeutic developments of benzothiazole containing compounds in the medicinal chemistry.